Sheidan Organ 头像。

Sheridan A. Organ

协理

Sheridan Organ is a member of the Health Care Practice. While attaining her master’s in public health, Sheridan worked as a Public Health Law Fellow at the Center for Disease Control and Prevention with a placement at the NYC Department of Health and Mental Hygiene and as a teaching fellow at Boston University.

During law school, Sheridan was selected for the Mayo-Foley Health Law Fellowship, consisting of summer internships with the Mayo Clinic Legal Department in Rochester, Minnesota and Foley’s Boston office. During this time, she assisted attorneys at both the Mayo Clinic and Foley with a broad range of regulatory compliance and transactional matters. While in law school, Sheridan also interned at Medical Legal Partnerships Boston where she supported law and policy consultants by conducting legal research for interdisciplinary communities of care teams.

演讲和出版物

  • Co-author, “Massachusetts: New Year, New Law — Governor Signs “An Act enhancing the market review process” (House Bill No. 5159),” Health Care Law Today (January 14, 2025)
2025年12月2日 今日医疗保健法

数字健康技术在临床试验中的应用:MAHA的支持与FDA最终指南的明确要求

数字健康技术(DHT)是美国卫生与公众服务部(HHS)部长小罗伯特·肯尼迪推动"让美国更健康"计划的核心组成部分。
2025 年 9 月 5 日 新闻

富理达律师为美国卫生法协会的《代表医生手册》撰稿

Foley & Lardner LLP 律师 Jana Kolarik、Claire Marblestone、Illana Meyer、Sheridan Organ 和 Kate Pamperin 为美国卫生法协会 (AHLA) 的《代表医生手册》第五版撰稿。
一个人一只手拿着胰岛素笔,另一只手拿开笔帽,表现出精准和细心,就像芝加哥的律师处理复杂的诉讼支持一样。
August 7, 2025 Health Care Law Today

GLP-1 Drugs: Ohio Board of Pharmacy Issues FAQs for Compounders

In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or pharmacies could compound drugs that were essentially copies of either semaglutide (available under the brand names Ozempic, Rybelsus, and Wegovy) and tirzepatide (available under the brand names Mounjaro, and Zepbound).
May 23, 2025 In the News

Foley Attorneys Publish on FDA's AI Medical Device Software Recommendations

Foley & Lardner LLP attorneys Kyle Faget, Nathan Beaver, David Rosen, and Sheridan Organ authored the MD+DI article, "FDA Outlines AI Medical Device Software Recommendations in Draft Guidance."
2025 年 5 月 15 日 今日医疗保健法

美国医疗器械协会发布《人工智能政策路线图》为监管机构提供指引

2025年3月14日,医疗技术协会AdvaMed发布了其人工智能政策路线图(以下简称路线图),该文件概述了...的政策优先事项。
2025 年 5 月 15 日 今日医疗保健法

药品定价:特朗普签署 "最惠国待遇 "行政令

2025 年 5 月 12 日,特朗普总统签署了其本届政府的第二项与药品定价相关的行政命令(EO)。虽然...